How Amgen uses GPT-5

Amgen is utilizing GPT-5 through the OpenAI API to enhance its biotechnology research and drug discovery pipelines. This integration allows the company to apply advanced large language model capabilities to complex biological data analysis and pharmaceutical development.

Technical Integration via OpenAI API

Amgen's implementation of GPT-5 is centered around the OpenAI API, enabling the company to integrate the model's reasoning and processing power into its own proprietary research workflows. By leveraging the API, Amgen can scale the analysis of biological information and automate the complex data synthesis required for drug discovery.

Impact on Biotechnology Research

Integrating GPT-5 into the pharmaceutical research process allows for more efficient processing of vast amounts of biological data. This capability is the primary driver for Amgen's adoption of the model, aiming to accelerate the timeline from initial research to the development of viable therapeutic candidates.

Context within OpenAI's Model Ecosystem

This partnership highlights the ongoing deployment of GPT-5 series models (including versions 5.4, 5.5, and 5.6) across specialized industrial sectors. Amgen's use case demonstrates the transition of frontier models from general-purpose assistants to specialized tools for high-stakes scientific research in biotechnology.